Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE

BACKGROUND: Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamen, Diane L, Wallace, Caroline, Li, Zihai, Wyatt, Megan, Paulos, Crystal, Wei, Chungwen, Wang, Hongjun, Wolf, Bethany J, Nietert, Paul J, Gilkeson, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277402/
https://www.ncbi.nlm.nih.gov/pubmed/35820718
http://dx.doi.org/10.1136/lupus-2022-000704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277402/
https://www.ncbi.nlm.nih.gov/pubmed/35820718
http://dx.doi.org/10.1136/lupus-2022-000704

Ejemplares similares